Voclosporin - Aurinia Pharmaceuticals

Drug Profile

Voclosporin - Aurinia Pharmaceuticals

Alternative Names: Luveniq; LX 211; LX 212; LX 214

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isotechnika
  • Developer Lux Biosciences
  • Class Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Blepharitis; Dry eyes; Uveitis

Most Recent Events

  • 03 Feb 2015 Voclosporin - Lux Biosciences is available for licensing as of 03 Feb 2015. http://www.auriniapharma.com/dnn/default.aspx
  • 03 Feb 2015 Voclosporin is covered by patents in Japan, China, USA, Mexico and Australia
  • 11 Sep 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top